Results 81 to 90 of about 9,439 (180)
Orexin 2 receptor agonists have demonstrated that targeting the orexin system may address symptoms of central disorders of hypersomnolence. Results of this phase 1 study support the phase 2 clinical evaluation of oral alixorexton in patients with IH, NT2 and NT1.
Ronald R. Grunstein +10 more
wiley +1 more source
Orexin-driven GAD65 network of the lateral hypothalamus sets physical activity in mice
Damage to the lateral hypothalamus (LH) causes profound physical inactivity in mammals. Several molecularly distinct types of LH neurons have been identified, including orexin cells and glutamic acid decarboxylase 65 (GAD65) cells, but their interplay in
Christin Kosse (8268174) +3 more
core
Orexin neurons regulate critical brain activities for controlling sleep, eating, emotions, and metabolism, and impaired orexin neuron function results in several neurologic disorders.
Koji Hayakawa +6 more
doaj +1 more source
Daridorexant‐ Case Report of Possible Side‐Effect in Rare Mitochondrial Disorder
ABSTRACT This case report describes a 40‐year‐old woman with maternally inherited diabetes and deafness (MIDD), a rare mitochondrial disorder, who received treatment with daridorexant due to severe chronic insomnia. She developed progression of her MIDD symptoms during treatment.
Sven Svedmyr, Joel Bergqvist
wiley +1 more source
The neuropeptides orexin A and B (also known as hypocretins) play an important role in many physiological and behavioral activities. Orexins are ligands of two closely related G-protein-coupled receptors, that are the named orexin 1 and orexin 2 ...
Annette G. Beck-Sickinger (92957) +4 more
core +1 more source
Paradoxical function of orexin/hypocretin circuits in a mouse model of Huntington's disease
Huntington's disease (HD) is a neurodegenerative disorder involving progressive motor disturbances, cognitive decline, and desynchronized sleep–wake rhythms.
Rhîannan H. Williams +2 more
doaj +1 more source
Using real‐world data, AAP augmentation patterns were evaluated in patients with MDD initially treated with antidepressant monotherapy. AAP augmentation therapy was initiated after a relatively long interval. Although only a small proportion of patients received this therapy, nearly half showed claims‐defined continuation for more than 6 months ...
Hikaru Hori +8 more
wiley +1 more source
Effects of Traumatic Brain Injury on the Orexin/Hypocretin System
Traumatic Brain Injuries (TBIs) are known to cause a myriad of symptoms in patients. One common symptom after injury is sleep disruptions. One neuropeptide system has been studied repeatedly as a potential cause of sleep disruptions after TBI- the orexin/
Rebecca T. Somach +2 more
doaj +1 more source
Insomnia affects around one in ten adults. In this 2‐year UK Medical Cannabis Registry cohort study of 211 adults with insomnia, treatment with cannabis‐based medicinal products was associated with a sustained improvement in self‐reported sleep quality across 24 months.
Aran Koye +7 more
wiley +1 more source
Parkinson’s disease (PD), classically defined as a progressive motor disorder accompanied with dopaminergic neuron loss and presence of Lewy bodies, is the second most common neurodegenerative disease.
Milos Stanojlovic +3 more
doaj +1 more source

